ribavirin

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

1 headnote for ribavirin

- Ribavirin

786 documents for ribavirin

- Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C.
First study to evaluate four-drug, 12-week treatment duration for hepatitis C BERLIN -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today ann...
- Business Wire
- March 31, 2011
- In 2015, Gilead's Gs-7977 Plus Ribavirin Will Earn Decision Resources' Proprietary Clinical Gold Standard Status for the Treatment of Non-Responder Patients with Hepatitis C Virus
GS-7977 Plus Ribavirin Will Displace the Current Proprietary Clinical Gold Standard, Telaprevir in Combination with Peg-IFNalpha/ Ribavirin, According to Findings from Decision Resources Decision Resources
- Business Wire
- February 28, 2012
- Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK[R], VX-222 and Ribavirin in People with Genotype 1 Hepatitis C.
- Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 w...
- Business Wire
- February 23, 2012

- Vertex Announces 12-Week On-Treatment Data and Svr4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of Incivek(R), Vx-222 and Ribavirin in People with Genotype 1 Hepatitis C
- Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks -__ - Vertex also announces the advancement of its broad portfolio of direct acting antivirals, including its two structurally-distinct nucleotide polymerase inhibitors -
- Business Wire
- March 06, 2012
- Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study.
* First presentation of interim data on Lambda in combination with the direct-acting antiviral (DAA) daclatasvir, from the global D-LITE study of geno...
- Business Wire
- November 12, 2012
- New Data From Abbvie's Phase Iib Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with Hcv Genotype 1 ; - 96 Percent of Treatment-Naive Patients and 93 Percent of Prior Null Responders Treated with Abbvie's Investigational Ifn-Free, Triple-Daa Combination Therapy Achieve Svr24; - Additional Analyses Looks at Response Rates in Patients with Differing Baseline Factors Including Gender, Viral Load and Fibrosis Stage
AMSTERDAM, April 23, 2013 /PRNewswire/ -- (NYSE: ABBV) - Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination. The triple-DAA combination is currently be...
- U.S. Newswire
- April 23, 2013
- Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naove Genotype 1 Hepatitis C Infected Patients.
- Phase 3 Study with a Fixed-Dose Combination Tablet of Sofosbuvir and GS-5885 Now Underway - BOSTON -- Gilead Sciences (Nasdaq: GILD) today announc...
- Business Wire
- November 10, 2012
- Gilead Announces Early Sustained Virologic Response Rates for Gs- 7977 Plus Ribavirin in Genotype 1 Treatment-Naive Hepatitis C Patients
- Interim Results Reported from ELECTRON and QUANTUM Studies - Gilead Sciences, Inc.
- Business Wire
- April 19, 2012
- Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study of Treatment-Naove Hepatitis C Patients.
Adverse event profile of regimen containing BMS-790052 was consistent with that of treatment with PEG-Interferon alfa and ribavirin alone PRINCETON,...
- Business Wire
- March 31, 2011
- Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of Gs-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients
- ATOMIC Data Demonstrate High Cure Rates in Genotype 1 Patients With 12 Weeks of Treatment - Gilead Sciences, Inc.
- Business Wire
- April 19, 2012